Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Alzheimer disease

Donepezil and nursing home placement — benefits and costs

Nature Reviews Neurology volume 12, pages 11–13 (2016)Cite this article

Subjects

The recent DOMINO-AD trial suggests that continued treatment with donepezil delays nursing home placement for patients with severe Alzheimer disease, but more work is needed to support strong conclusions about whether the benefits outweigh the costs.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Jelic, V. & Darreh-Shori, T. Donepezil: a review of pharmacological characteristics and role in the management of Alzheimer disease. Clin. Med. Insights Ther. 2, 771–788 (2010).

    CAS  Google Scholar 

  2. Howard, R. et al. Nursing home placement in the Donepezil and Memantine in Moderate to Severe Alzheimer's Disease (DOMINO-AD) trial: secondary and post-hoc analyses. Lancet Neurol. 14, 1171–1181 (2015).

    Article  Google Scholar 

  3. Johnell, K., Religa, D. & Eriksdotter, M. Differences in drug therapy between dementia disorders in the Swedish dementia registry: a nationwide study of over 7,000 patients. Dement. Geriatr. Cogn. Disord. 35, 239–248 (2013).

    Article  CAS  Google Scholar 

  4. Birks, J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst. Rev. 1, CD005593 (2006).

    Google Scholar 

  5. Schmidt, R. et al. EFNS-ENS/EAN guideline on concomitant use of cholinesterase inhibitors and memantine in moderate to severe Alzheimer's disease. Eur. J. Neurol. 22, 889–898 (2015).

    Article  CAS  Google Scholar 

  6. Wimo, A. Cost effectiveness of cholinesterase inhibitors in the treatment of Alzheimer's disease: a review with methodological considerations. Drugs Aging 21, 279–295 (2004).

    Article  CAS  Google Scholar 

  7. Courtney, C. et al. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet 363, 2105–2115 (2004).

    Article  CAS  Google Scholar 

  8. Wimo, A. Long-term effects of Alzheimer's disease treatment. Lancet Neurol. 14, 1145–1146 (2015).

    Article  Google Scholar 

  9. Huybrechts, K. F. et al. Variation in antipsychotic treatment choice across US nursing homes. J. Clin. Psychopharmacol. 32, 11–17 (2012).

    Article  Google Scholar 

  10. Johnell, K. & Fastbom, J. Comparison of prescription drug use between community-dwelling and institutionalized elderly in Sweden. Drugs Aging 29, 751–758 (2012).

    Article  Google Scholar 

Download references

Author information

Author notes

  1. Vesna Jelic and Bengt Winblad: V.J. and B.W. contributed equally to this article.

Authors and Affiliations

  1. Department of Neurobiology, Care Sciences and Society, Center for Alzheimer Research, Karolinska Institute, Stockholm, SE-171 77, Sweden

    Vesna Jelic & Bengt Winblad

Authors
  1. Vesna Jelic
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bengt Winblad
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bengt Winblad.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Jelic, V., Winblad, B. Donepezil and nursing home placement — benefits and costs. Nat Rev Neurol 12, 11–13 (2016). https://doi.org/10.1038/nrneurol.2015.237

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrneurol.2015.237

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing